Is breastfeeding for HIV-positive mothers now recommendable?

It is time that high-income countries move towards less rigid recommendations about infant feeding.

Obesity-related respiratory failure: a new area for extracorporeal lung support?

In the ICU, the main challenges with obese patients are to take into account the pulmonary pathophysiological characteristics when choosing the best management options.

Is breastfeeding an equipoise option in effectively treated HIV-infected mothers in a high-income setting?

Low rates of mother-to-child transmission of HIV via breast milk whilst mothers are on cART in low-resource settings question whether a recommendation to abstain from breastfeeding in high-income countries is still justified.

Diagnosis and treatment of follicular lymphoma: an update

Over the last few years, there have been many changes in the management of patients with follicular lymphoma, resulting in improvements in progression-free survival and quality of life.

Ovarian cancer in Switzerland: incidence and treatment according to hospital registry data

For the first time in Switzerland, the Swiss hospital registry was used to examine the incidence of ovarian cancer as well as its treatment episodes and costs.

Awareness, approval and completion of advance directives in older adults in Switzerland

Switzerland introduced legally binding advance directives 2013. But there is still no comprehensive evidence on older persons’ awareness, attitudes and behaviours with regard to advance directives in Switzerland.

Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)

The majority of germ cell tumours can be cured by orchiectomy followed by active surveillance or systemic and/or local treatments. There are various guidelines for a structured follow-up including radiographic and clinical examinations.

In-vitro characterisation of a novel antimicrobial agent, TNP-2092, against Helicobacter pylori clinical isolates

TNP-2092 is a novel dual-action compound consisting of rifamycin SV and 4H-4-oxo- quinolizine pharmacophoresand is currently in the early stage of clinical development for Helicobacter pylori infection.